- Home
- Publications
- Publication Search
- Publication Details
Title
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review
Authors
Keywords
-
Journal
CLINICAL PHARMACOKINETICS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-05-14
DOI
10.1007/s40262-019-00775-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation
- (2018) Satoshi Ueshima et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Apixaban and Rosuvastatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease
- (2018) Rommel G. Tirona et al. DRUG METABOLISM AND DISPOSITION
- Regional Gastrointestinal Absorption of Apixaban in Healthy Subjects
- (2018) Wonkyung Byon et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Antithrombotic Therapy for Atrial Fibrillation
- (2018) Gregory Y.H. Lip et al. CHEST
- Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study
- (2017) Y. Song et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation
- (2017) Satoshi Ueshima et al. Pharmacogenetics and Genomics
- Apixaban pharmacodynamic activity in umbilical cord, paediatric, and adult plasma
- (2017) Robert Yetman et al. THROMBOSIS AND HAEMOSTASIS
- Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa
- (2016) Blisse Vakkalagadda et al. American Journal of Cardiovascular Drugs
- Evaluation of Crushed Tablet for Oral Administration and the Effect of Food on Apixaban Pharmacokinetics in Healthy Adults
- (2016) Yan Song et al. CLINICAL THERAPEUTICS
- The ‘obesity paradox’ in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial
- (2016) Roopinder K. Sandhu et al. EUROPEAN HEART JOURNAL
- Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors
- (2016) Stuart J. Connolly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial
- (2015) Kuan H. Ng et al. AGE AND AGEING
- Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
- (2015) Charles E. Frost et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Effects of Age and Sex on the Single-Dose Pharmacokinetics and Pharmacodynamics of Apixaban
- (2015) Charles E. Frost et al. CLINICAL PHARMACOKINETICS
- Relative Bioavailability of Apixaban Solution or Crushed Tablet Formulations Administered by Mouth or Nasogastric Tube in Healthy Subjects
- (2015) Yan Song et al. CLINICAL THERAPEUTICS
- Randomized, blinded, placebo- and positive-controlled crossover study to determine the effect of multiple doses of apixaban on the QTc interval
- (2015) Charles Frost et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis
- (2015) Xiaoli Wang et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban
- (2015) Ming Chang et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
- (2015) Deborah M. Siegal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update
- (2014) Qingcheng Mao et al. AAPS Journal
- Efficacy and Safety of Apixaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation from East Asia: A Subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
- (2014) Shinya Goto et al. AMERICAN HEART JOURNAL
- Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban
- (2014) Charles Frost et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial
- (2014) S. Halvorsen et al. EUROPEAN HEART JOURNAL
- LC–MS/MS determination of apixaban (BMS-562247) and its major metabolite in human plasma: an application of polarity switching and monolithic HPLC column
- (2014) Janice Pursley et al. Bioanalysis
- Effect of Activated Charcoal on Apixaban Pharmacokinetics in Healthy Subjects
- (2013) Xiaoli Wang et al. American Journal of Cardiovascular Drugs
- Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects
- (2013) Vijay V. Upreti et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects
- (2013) Charles Frost et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Oral Apixaban for the Treatment of Acute Venous Thromboembolism
- (2013) Giancarlo Agnelli et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
- (2012) Charles Frost et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- A Novel Prothrombin Time Assay for Assessing the Anticoagulant Activity of Oral Factor Xa Inhibitors
- (2012) Yu Chen Barrett et al. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
- Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups
- (2012) G. F. PINEO et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Apixaban for Extended Treatment of Venous Thromboembolism
- (2012) Giancarlo Agnelli et al. NEW ENGLAND JOURNAL OF MEDICINE
- A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects
- (2012) Jessie Wang et al. THROMBOSIS AND HAEMOSTASIS
- Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor
- (2011) Kan He et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor
- (2011) Pancras C. Wong et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- Apixaban in Patients with Atrial Fibrillation
- (2011) Stuart J. Connolly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apixaban versus Warfarin in Patients with Atrial Fibrillation
- (2011) Christopher B. Granger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Quantification of Apixaban's Therapeutic Utility in Prevention of Venous Thromboembolism: Selection of Phase III Trial Dose
- (2010) T A Leil et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Tissue Distribution and Elimination of [14C]Apixaban in Rats
- (2010) L. Wang et al. DRUG METABOLISM AND DISPOSITION
- Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma
- (2010) Joseph M. Luettgen et al. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
- Comparative Validation of a Novel Risk Score for Predicting Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation
- (2010) Gregory Y.H. Lip et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial
- (2010) Michael Rud Lassen et al. LANCET
- Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement
- (2010) Michael Rud Lassen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparative Metabolism of 14C-Labeled Apixaban in Mice, Rats, Rabbits, Dogs, and Humans
- (2009) D. Zhang et al. DRUG METABOLISM AND DISPOSITION
- In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction Studies
- (2009) L. Wang et al. DRUG METABOLISM AND DISPOSITION
- Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement
- (2009) Michael Rud Lassen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro
- (2009) Xiaosui Jiang et al. THROMBOSIS AND HAEMOSTASIS
- Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans
- (2008) N. Raghavan et al. DRUG METABOLISM AND DISPOSITION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started